Quarterly & Annual Financial Results
Neogen Chemicals Reports Strong Q4 FY26 Performance; Revenue Up 22% YoY
NSE
neogen
BSE
542665
Neogen Chemicals reported strong Q4 FY26 consolidated performance with revenue rising 22% YoY to ₹247 crore and EBITDA increasing 21% YoY to ₹44 crore. The company also recommended a final dividend of ₹1 per equity share and highlighted progress in battery chemicals expansion projects.
PRICE-SENSITIVE TRIGGER
Event: Neogen Chemicals announced audited Q4 FY26 and FY26 financial results.
Type: Quarterly & Annual Financial Results
Impact: Positive
Immediate Effect: Strong revenue growth, operational resilience, promoter capital infusion, and progress in battery material expansion projects strengthened investor confidence despite ongoing transition costs and geopolitical disruptions.
Key Metrics:
Q4 FY26 (Consolidated):
- Revenue:
- ₹247 crore, up 22% YoY
- Gross Profit:
- ₹110 crore, up 15% YoY
- EBITDA:
- ₹44 crore, up 21% YoY
- EBITDA Margin:
- 17.8%
- PAT:
- ₹11 crore, up 373% YoY
- EPS:
- ₹4.32 per share (not annualized)
FY26 (Consolidated):
- Revenue:
- ₹862 crore, up 11% YoY
- Gross Profit:
- ₹396 crore, up 12% YoY
- EBITDA:
- ₹137 crore, up 1% YoY
- PAT:
- ₹29 crore, down 17% YoY
Additional Financial Updates:
- Dividend recommended:
- ₹1 per equity share
- Promoter equity infusion:
- ₹161 crore through preferential allotment
- Insurance claim received till date:
- ₹140 crore
- Net insurance claim receivable:
- ₹203 crore
Highlight Metric:
- Q4 Revenue Growth: 22% YoY to ₹247 crore.
What Happened ?
Neogen Chemicals delivered a strong Q4 FY26 despite operational headwinds from the Dahej plant transition, elevated input costs, and geopolitical supply-chain disruptions in the Middle East. The company’s growth was driven by rising volumes, sustained high plant utilization, and pass-through mechanisms for higher raw material costs.
The company also highlighted significant progress in its battery chemicals and lithium-ion materials expansion projects through subsidiary Neogen Ionics.
Management stated that FY27 is expected to be transformative as the company commissions one of India’s largest greenfield battery material facilities at Pakhajan.
Key Details
Operational Performance:
- EBITDA margins remained stable at 17.8% despite:
- Dahej transition costs
- Neogen Ionics expansion overheads
- Geopolitical supply disruptions
- Strong plant utilization supported topline growth.
- Input cost inflation is largely pass-through in nature.
Battery Chemicals Expansion:
- Pakhajan Greenfield Project timelines remain unchanged:
- Electrolyte plant:
- H1 FY27
- Electrolyte salts:
- H2 FY27
- Electrolyte plant:
- Dahej facility:
- 2,000 MT electrolyte capacity fully commissioned.
- Trial production ongoing for additional lithium electrolyte salt capacities.
Capital & Funding:
- Board approved preferential allotment of:
- 10 lakh shares to promoter group entity.
- Total capital infusion:
- ₹161 crore at ₹1,610/share.
- Funds to be used for:
- Battery material expansion
- Working capital
- General corporate purposes
Fire Incident Update:
- Reconstruction of replacement Dahej plant remains on track.
- Commissioning expected:
- June 2026.
- Insurance recoveries continue to support operations.
Note:
- The aggregate revised project cost for Dahej Phase 1 and Pakhajan Phase 2 battery material projects now stands at ₹1,795 crore.
Risk Analysis
Key Risks:
- Delays in commercialization of battery material projects.
- Elevated finance costs due to heavy capex deployment.
- Dependence on customer qualification approvals for battery materials.
- Geopolitical disruptions affecting raw material and logistics costs.
- Execution risk in scaling up large greenfield projects.
Worst Case Scenario:
- If commercialization timelines for battery chemicals projects slip significantly or demand visibility weakens, margin pressure and higher debt servicing costs could impact profitability.
Risk Level: Medium
Company Commentary
- Neogen remains confident about long-term growth in battery materials.
- FY27 is expected to be a transformative year for the company.
- Customer approvals and commercialization activities are progressing positively.
- Management expects standalone operations to return to normalized growth trajectory post Dahej commissioning.
Official Exchange Filing: Neogen Chemicals Limited